Novartis Bioventures Ltd 4
4 · Galera Therapeutics, Inc. · Filed Jun 12, 2020
Insider Transaction Report
Form 4
Novartis Bioventures Ltd
10% Owner
Transactions
- Sale
Common Stock
2020-06-12$9.19/sh−1,500$13,785→ 3,489,559 total - Sale
Common Stock
2020-06-11$9.21/sh−7,200$66,312→ 3,491,059 total - Sale
Common Stock
2020-06-10$9.46/sh−8,532$80,713→ 3,498,259 total
Footnotes (4)
- [F1]Reflects sales of common stock executed in multiple transactions at prices ranging from $9.19 to $9.74. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F2]Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
- [F3]Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.39. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F4]Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.38. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.